Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, Reis-Filho JS, Cohen O, Wagle N, Nardone A, Jeselsohn R, Brown M, Rimawi MF, Osborne CK, Schiff R. Fu X, et al. Among authors: chamness gc. Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):26823-26834. doi: 10.1073/pnas.1911584116. Epub 2019 Dec 11. Proc Natl Acad Sci U S A. 2019. PMID: 31826955 Free PMC article.
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R. Giuliano M, et al. Among authors: chamness gc. Clin Cancer Res. 2015 Sep 1;21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728. Epub 2015 May 26. Clin Cancer Res. 2015. PMID: 26015514 Free PMC article.
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.
Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. Xu X, et al. Among authors: chamness gc. Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9. Clin Cancer Res. 2017. PMID: 28487443 Free PMC article.
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R. Nardone A, et al. Among authors: chamness gc. Br J Cancer. 2019 Feb;120(3):331-339. doi: 10.1038/s41416-018-0354-9. Epub 2018 Dec 17. Br J Cancer. 2019. PMID: 30555156 Free PMC article.
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff R. Sethunath V, et al. Among authors: chamness gc. Mol Cancer Res. 2019 Nov;17(11):2318-2330. doi: 10.1158/1541-7786.MCR-19-0756. Epub 2019 Aug 16. Mol Cancer Res. 2019. PMID: 31420371 Free PMC article.
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R. Wang YC, et al. Among authors: chamness gc. Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28. Breast Cancer Res. 2011. PMID: 22123186 Free PMC article.
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Li X, et al. Among authors: chamness gc. J Natl Cancer Inst. 2008 May 7;100(9):672-9. doi: 10.1093/jnci/djn123. Epub 2008 Apr 29. J Natl Cancer Inst. 2008. PMID: 18445819
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Dave B, et al. Among authors: chamness gc. J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6. J Clin Oncol. 2011. PMID: 21135276 Free PMC article.
106 results